Biotechnology Innovator Juvena Therapeutics Appoints Industry Veteran Julie Anne Smith as CEO Amidst Pivotal Clinical Trials
FOSTER CITY, CA – [Date of Publication] – Juvena Therapeutics, a dynamic California-based biotechnology firm at the forefront of AI-powered therapeutic discovery, today announced the appointment of highly respected industry leader Julie Anne Smith as its new Chief Executive Officer. Smith will also join the company’s esteemed Board of Directors, bringing a wealth of experience and strategic vision to Juvena at a critical juncture in its growth.
Smith’s appointment arrives as Juvena embarks on a significant Phase IIa atrophy study for its groundbreaking first-in-class biologic, JUV-161. This novel therapeutic has already garnered Orphan Drug status from the U.S. FDA for myotonic dystrophy, highlighting its potential to address a significant unmet medical need.
Julie Anne Smith’s illustrious career spans over two decades of leadership in the biotechnology and pharmaceutical sectors. Most recently, she served as CEO of Nuvig Therapeutics and previously held the position of President and CEO at Escape Bio. Her strategic acumen and deep industry knowledge are further evidenced by her current board directorships at Stoke Therapeutics and Exelixis. Smith’s expertise is particularly pronounced in the development of therapeutics for rare diseases, neuromuscular conditions, and autoimmune disorders – areas directly aligned with Juvena’s focus.
Earlier in her career, Smith served as President and CEO of Raptor Pharmaceuticals, a company successfully acquired by Horizon Pharmaceuticals in 2016. Her extensive leadership track record also includes pivotal roles at Enobia Pharma, Jazz Pharmaceuticals, Genzyme, and Bristol Myers Squibb, underscoring her ability to navigate complex scientific landscapes and drive successful drug development.
A New Chapter with Significant Clinical Momentum
Smith’s leadership comes at an exciting time for Juvena. The company’s lead candidate, JUV-161, represents a significant advancement, having been discovered through Juvena’s proprietary AI-enabled platform, JuvNET. This innovative platform maps the therapeutic potential of stem cell-secreted proteins, offering a novel approach to drug discovery. Beyond JUV-161, Juvena is actively leveraging the JuvNET platform to advance additional muscle and metabolic health programs in collaboration with pharmaceutical giant Eli Lilly and Company, signaling broad potential for their technological advancements.
In her first public remarks as CEO, Smith expressed her enthusiasm for Juvena’s unique position at the intersection of cutting-edge science and clinical translation. "Juvena has built something rare: a discovery platform at the intersection of biology, AI, and clinical translation," Smith stated. "I’ve spent my career on therapies that change the trajectory of disease for people with few or no options. JUV-161 can do that for people living with progressive muscle disease."
Stephen Juelsgaard, DVM, JD, Independent Director of Juvena Therapeutics, echoed the sentiment of excitement and confidence in Smith’s leadership. "Julie has led other clinical-stage companies through pivotal decisions, built teams that attract top talent and partners, and kept the focus on the patients," Juelsgaard commented. "With Phase I completed and our Lilly collaboration adding momentum, this is the right moment for Julie’s caliber of leadership."
This strategic appointment signals Juvena Therapeutics’ commitment to accelerating its clinical programs and solidifying its position as a leader in innovative therapeutic development, particularly for patients grappling with debilitating muscle diseases. The convergence of an experienced leader like Julie Anne Smith with a promising clinical pipeline and a powerful AI-driven discovery platform positions Juvena for significant future success.
For more insights into executive movements within the industry, please see our coverage of other industry executive team appointments and promotions here.
